

PTO/SB/21 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	10/702,681
		Filing Date	November 5, 2003
		First Named Inventor	Deborah A. RATHJEN
		Art Unit	Not Yet Assigned
		Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	33 + 1 reference	Attorney Docket Number	273402602309

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement - 4 pages <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Form PTO-1449 + copy - 28 pages Return Receipt Postcard
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	MORRISON & FOERSTER LLP (Customer No. 25226) Kimberly A. Bolin - 44,546
Signature	
Date	February 18, 2004

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: February 18, 2004

Signature:


(Aurelia A. Caparas)



PATENT
Docket No. 273402602309
Client Reference: 501927

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on February 18, 2004.


Aurelia A. Caparas

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Deborah A. RATHJEN et al.

Serial No.: 10/702,681

Filing Date: November 5, 2003

For: TUMOUR NECROSIS FACTOR
BINDING LIGANDS

Examiner: Not Yet Assigned

Group Art Unit: Not Yet Assigned

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copy of Reference No. 5 of the Form PTO-1449 is included herewith. Copies of the other documents listed on the Form PTO-1449 were previously submitted in Information Disclosure Statements and Office Actions, directed to the U.S. Patent Application No. 10/265,451, filed October 3, 2002, and U.S. Patent Application No. 09/364,039, filed July 30, 1999, and accordingly copies

are not included herewith. This protocol conforms with 37 C.F.R. §1.98(d) and M.P.E.P. 609(A)(2). The Examiner is requested to make these documents of record in the application. Please note that if the Examiner requires additional copies of the documents, the Applicants will be happy to provide them upon request.

Additionally, Applicants bring to the attention of the Examiner the following information and patent applications: The present application is a continuation of U.S. Patent Application No. 10/453,176, filed June 2, 2003 (Publication No. 2003-0232971), which is a continuation of U.S. Patent Application No. 10/359,934 (Publication No. 2003-0225254), filed February 7, 2003, which in turn is a continuation of U.S. Patent Application No. 10/327,541, filed December 20, 2002 (Publication No. 2004-0002588), which is a Continuation of U.S. Patent Application No. 10/265,451, filed October 3, 2002 (Publication No. 2003-0162948) and, accordingly, copies are not included herewith.

Finally, Applicants is also bringing to the attention of the Examiner the co-pending applications referred on the Form PTO-1449 as Reference Nos. 2-20 (included) and U.S. Patent Application No. 10/346,499, by Deborah A. Rathjen et al., filed January 15, 2003, which has not yet been published.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
- ☐ A fee is required. A check in the amount of ___ is enclosed.

- ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
- ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly; no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of __ is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. §1.17(p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing **273402602309**.



However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.


Dated: February 17, 2004

Respectfully submitted,

By: 

Kimberly A. Bolin
Registration No. 44,546

Morrison & Foerster LLP
755 Page Mill Road
Palo Alto, California 94304-1018
Telephone: (650) 813-5740
Facsimile: (650) 494-0792



Form PTO-449 SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 35%;">Docket Number 273402602309</td> <td style="width: 65%;">Application Number 10/702,681</td> </tr> <tr> <td colspan="2" style="padding: 5px;">Applicant <div style="text-align: center;">Deborah A. RATHJEN et al.</div></td> </tr> <tr> <td style="padding: 5px;">Filing Date November 5, 2003</td> <td style="padding: 5px;">Group Art Unit Not Yet Assigned</td> </tr> <tr> <td colspan="2" style="padding: 5px;">Mailing Date February 18, 2004</td> </tr> </table>	Docket Number 273402602309	Application Number 10/702,681	Applicant <div style="text-align: center;">Deborah A. RATHJEN et al.</div>		Filing Date November 5, 2003	Group Art Unit Not Yet Assigned	Mailing Date February 18, 2004	
Docket Number 273402602309	Application Number 10/702,681								
Applicant <div style="text-align: center;">Deborah A. RATHJEN et al.</div>									
Filing Date November 5, 2003	Group Art Unit Not Yet Assigned								
Mailing Date February 18, 2004									

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	01/24/2002	2002/0010180	Fedlmann et al.			
	2.	07/17/2003	2003/0135029	Rathjen et al.			
	3.	07/24/2003	2003/0139577	Rathjen et al.			
	4.	07/24/2003	2003/0139580	Rathjen et al.			
	5.	08/28/2003	2003/0162948	Rathjen et al.			
	6.	09/04/2003	2003/0166874	Rathjen et al.			
	7.	09/11/2003	2003/0170204	Rathjen et al.			
	8.	09/11/2003	2003/0171553	Rathjen et al.			
	9.	09/11/2003	2003/0171554	Rathjen et al.			
	10.	09/11/2003	2003/0171555	Rathjen et al.			
	11.	10/23/2003	2003/0199678	Rathjen et al.			
	12.	11/06/2003	2003/0208047	Rathjen et al.			
	13.	11/06/2003	2003/0208049	Rathjen et al.			
	14.	11/20/2003	2003/0216552	Rathjen et al.			
	15.	12/04/2003	2003/0225254	Rathjen et al.			
	16.	12/18/2003	2003/0232970	Rathjen et al.			
	17.	12/18/2003	2003/0232971	Rathjen et al.			
	18.	01/01/2004	2004/0002588	Rathjen et al.			
	19.	01/01/2004	2004/0002589	Rathjen et al.			
	20.	01/01/2004	2004/0002590	Rathjen et al.			
	21.	07/29/1986	4,603,106	Cerami et al.			
	22.	04/18/1989	4,822,776	Cerami et al.			
	23.	09/26/1989	4,870,163	Rubin et al.			
	24.	12/24/1991	5,075,236	Yone et al.			
	25.	02/02/1993	5,183,657	Buurman			
	26.	07/06/1993	5,225,539	Winter			

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

Form PTO-1449 SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 273402602309	Application Number 10/702,681
	Applicant Deborah A. RATHJEN et al.	
	Filing Date November 5, 2003	Group Art Unit Not Yet Assigned
	Mailing Date February 18, 2004	

	27.	07/27/1993	5,231,024	Moeller et al.			
	28.	08/17/1993	5,237,024	Allberry et al.			
	29.	11/01/1994	5,360,716	Ohmoto et al.			
	30.	03/07/1995	5,395,760	Smith et al.			
	31.	06/25/1996	5,530,101	Queen et al.			
	32.	12/17/1996	5,585,089	Queen et al.			
	33.	07/01/1997	5,644,034	Rathjen et al.			
	34.	08/12/1997	5,656,272	Le et al.			
	35.	08/19/1997	5,658,803	Kuo			
	36.	09/30/1997	5,672,347	Aggarwal et al.			
	37.	12/02/1997	5,693,761	Queen et al.			
	38.	12/02/1997	5,693,762	Queen et al.			
	39.	12/16/1997	5,698,195	Le et al.			
	40.	12/16/1997	5,698,419	Wolpe et al.			
	41.	01/27/1998	5,712,155	Smith et al.			
	42.	07/21/1998	5,782,792	Jones et al.			
	43.	08/18/1998	5,795,967	Aggarwal et al.			
	44.	09/15/1998	5,808,029	Brockhaus et al.			
	45.	07/06/1999	5,919,452	Le et al.			
	46.	09/28/1999	5,959,087	Rathjen et al.			
	47.	07/18/2000	6,090,382	Salfeld et al.			
	48.	01/30/2001	6,180,370	Queen et al.			
	49.	03/13/2001	6,201,105	Smith et al.			
	50.	07/10/2001	6,258,562	Salfeld et al.			
	51.	08/21/2001	6,277,969	Le et al.			
	52.	09/04/2001	6,284,471	Le et al.			
	53.	07/09/2002	6,416,757	Rathjen et al.			
	54.	07/09/2002	6,417,158	Hauptmann et al.			
	55.	09/10/2002	6,448,380	Rathjen et al.			
	56.	09/17/2002	6,451,983	Rathjen et al.			

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

Form PTO-1449

SUPPLEMENTAL INFORMATION
DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 273402602309

Application Number 10/702,681

Applicant

Deborah A. RATHJEN et al.

Filing Date November 5, 2003

Group Art Unit Not Yet Assigned

Mailing Date February 18, 2004

	57.	12/24/2002	6,498,237	Rathjen et al.			
	58.	01/21/2003	6,509,015	Salfeld et al.			
	59.	04/15/2003	6,548,640	Winter			
	60.	06/03/2003	6,572,852	Smith et al.			
	61.	07/15/2003	6,593,458	Rathjen et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation	
							YES	NO
	62.	03/17/1983	EP 0 101 681	Europe				
	63.	07/09/1986	EP 0 186 833	Europe				
	64.	03/04/1987	EP 0 212 489	Europe				
	65.	04/22/1987	EP 0 218 868	Europe				
	66.	09/30/1987	EP 0 239 400	Europe				
	67.	03/23/1988	EP 0 260 610	Europe			Abstract	
	68.	10/26/1988	EP 0 288 088	Europe				
	69.	03/22/1989	EP 0 308 378	Europe				
	70.	01/17/1990	EP 0 350 690	Europe			Abstract	
	71.	01/24/1990	EP 0 351 789	Europe				
	72.	05/02/1990	EP 0 366 043	Europe				
	73.	08/01/1990	EP 0 380 068	Europe				
	74.	10/24/1990	EP 0 393 438	Europe			Abstract	
	75.	11/22/1990	EP 0 398 327	Europe				
	76.	02/13/1991	EP 0 412 486	Europe				
	77.	06/26/1991	EP 0 433 900	Europe				
	78.	10/16/1991	EP 0 451 216	Europe				
	79.	05/27/1992	EP 0 486 526	Europe				
	80.	10/27/1993	EP 0 566 647	Europe				
	81.	08/17/1994	EP 0 610 201	Europe				

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

**SUPPLEMENTAL INFORMATION
DISCLOSURE CITATION
IN AN APPLICATION**

(Use several sheets if necessary)

Docket Number 273402602309

Application Number 10/702,681

Applicant

Deborah A. RATHJEN et al.

Filing Date November 5, 2003

Group Art Unit Not Yet Assigned

Mailing Date February 18, 2004

	82.	11/15/1995	EP 0 682 040	Europe				
	83.	05/09/2001	EP 1 097 945	Europe				
	84.	10/07/1987	GB 2,188,638	Great Britain				
	85.	04/25/1988	JP 63-093799	Japan			Abstract	
	86.	10/26/1989	JP 1-268645	Japan				
	87.	02/21/1991	WO 91/02078	WIPO				
	88.	07/11/1991	WO 91/09967	WIPO				
	89.	01/23/1992	WO 92/01047	WIPO				
	90.	04/01/1993	WO 93/06213	WIPO				

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	91.	Abbas, A.K. and Lichtman, A.H. (2003). Schematic Diagram of a Secreted IgC Molecule <i>In Cellular and Molecular Immunology</i> Fifth Edition, Saunders, Elsevier: USA, one page.
	92.	Aggarwal, B. et al. (1985). "Human Tumor Necrosis Factor. Production, Purification, and Characterization," <i>J. Biol. Chem.</i> 260(4):2345-2354.
	93.	Akama, H. et al. (1990). "Mononuclear Cells Enhance Prostaglandin E ₂ Production of Polymorponuclear Leukocytes Via Tumor Necrosis Factor α ," <i>Biochemical and Biophysical Research Communications</i> 168(2):857-862.
	94.	Alzani, R. et al. (1995). "Mechanism of Suramin-Induced Deoligomerization of Tumor Necrosis Factor α ," <i>Biochemistry</i> 34(19):6344-6350.
	95.	Ameloot, P. et al. (2001). "Identification of Tumor Necrosis Factor (TNF) Amino Acids Crucial for Binding to the Murine p75 TNF Receptor and Construction of Receptor-selective Mutants," <i>J. Biol. Chem.</i> 276(40):37426-37430.
	96.	Appeal file history against the Decision of Opposition Division of European Patent Office dated November 11, 1999, of Application No. 90911467.0, Opposition No. 2116, Publication No. 0 486 526, Appeal Proceedings No. T0129/00-334 (01/24/2000-09/13/2000), pages 1-62.
	97.	Arend, W.P. (2002). "The Mode of Action of Cytokine Inhibitors," <i>J. Rheumatol.</i> 29(S65):16-21.
	98.	Arendt, A. et al. (1993) "Optimization of Peptide Synthesis on Polyethylene Rods," <i>Pept. Res.</i> 6(6):346-352.
	99.	Aston, R. et al. (1985) "Monoclonal antibodies to growth hormone and prolactin" <i>Pharmac. Therapeut.</i> 27:403-424.
	100.	Aston, R. et al. (1989) "Antibody-mediated enhancement of hormone activity," <i>Mol. Immunol.</i>

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Docket Number 273402602309	Application Number 10/702,681
		Applicant Deborah A. RATHJEN et al.	
		Filing Date November 5, 2003	Group Art Unit Not Yet Assigned
		Mailing Date February 18, 2004	
		26(5):435-446.	
	101.	Atherton, E. et al. (1975). "Polyamide Supports for Polypeptide Synthesis," <i>Journal of the American Chemical Society</i> 97(22):6584-6585.	
	102.	Atherton, E. et al. (1978). "A Mild Procedure for Solid Phase Peptide Synthesis: Use of Fluorenylmethoxycarbonylamino-acids," <i>J.C.S. Chem. Comm.</i> pp.537-539.	
	103.	Aujame, L. et al. (1997). "High Affinity Human Antibodies by Phage Display," <i>Human Antibodies</i> 8(4):155-168.	
	104.	Banner, D.W. et al. (1993). "Crystal Structure of the Soluble Human 55 kd TNF Receptor-Human TNF β Complex: Implications for TNF Receptor Activation," <i>Cell</i> 73:431-445.	
	105.	Barbas, C.F. III et al. (1993). "High Affinity Self-Reactive Human Antibodies by Design and Selection: Targeting the Integrin Ligand Binding Site," <i>Proc. Natl. Acad. Sci. USA</i> 90:10003-10007.	
	106.	Barbas, C.F. III et al. (1994). "In vitro Evolution of a Neutralizing Human Antibody to Human Immunodeficiency Virus Type 1 to Enhance Affinity and Broaden Strain Cross-Reactivity," <i>Proc. Natl. Acad. Sci. USA</i> 91:3809-3813.	
	107.	Beutler, B. et al. (1985). "Identity of Tumour Necrosis Factor and the Macrophage-Secreted Factor Cachectin," <i>Nature</i> 316:552-554.	
	108.	Beutler, B. et al. (1985). "Purification of Cachectin, A Lipoprotein Lipase-Suppressing Hormon Secreted by Endotoxin-Induced Raw 264.7 Cells," <i>J. Exp. Med.</i> 161:984-995.	
	109.	Beutler, B. et al. (1985). "Passive Immunization Against Cachectin/Tumor Necrosis Factor Protects Mice from Lethal Effect of Endotoxin," <i>Science</i> 229:869-871.	
	110.	Bevilacqua, M.P. et al. (June 1986). "Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1," <i>Proc. Natl. Acad. Sci. USA Medical Sciences</i> 83:4533-4537.	
	111.	Boekstegers, P. et al. (1994). "Changes in Skeletal Muscle PO ₂ , After Administration of Anti-TNF α -Antibody in Patients With Severe Sepsis: Comparison to Interleukin-6 Serum Levels, Apache II, and Elebute Scores," <i>Shock</i> 1:246-253.	
	112.	Brennan, F.M. et al. (1989). "Inhibitory Effect of the TNF α Antibodies on Synovial Cell Interleukin-1 Production in Rheumatoid Arthritis," <i>The Lancet</i> pp 244-247.	
	113.	Bringman, T. et al. (1987) "Monoclonal antibodies to human tumor necrosis factors alpha and beta: application for affinity purification, immunoassays, and as structural probes" <i>Hybridoma</i> 6(5):489-507.	
	114.	Burton, D.R. and Barbas, C.F. (1992). "Antibodies From Libraries," <i>Nature</i> 359(6398):782-783.	
	115.	Burton, D.R. and Barbas, C.F. (1994). "Human Antibodies From Combinatorial Libraries," <i>Adv. Immunol.</i> 57:191-280.	
	116.	Burton, D.R. et al. (1991). "A Large Array of Human Monoclonal Antibodies to Type 1 Human Immunodeficiency Virus From Combinatorial Libraries of Asymptomatic Seropositive Individuals," <i>Proc. Natl. Acad. Sci. USA</i> 88:10134-10137.	
EXAMINER:		DATE CONSIDERED:	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			

Form PTO-1449 SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Docket Number 273402602309	Application Number 10/702,681
		Applicant Deborah A. RATHJEN et al.	
		Filing Date November 5, 2003	Group Art Unit Not Yet Assigned
		Mailing Date February 18, 2004	
	117.	Cerami, A. et al. (1985). "Weight Loss Associated With an Endotoxin-Induced Mediator From Peritoneal Macrophages: The Role of Cachectin (Tumor Necrosis Factor)," <i>Immunol. Lett.</i> 11:173-177.	
	118.	Choulier, L. et al. (2002). "Comparative Properties of Two Peptide-Antibody Interactions as Deduced From Epitope Delineation," <i>J. Immunol. Methods</i> 259(1-2):77-86.	
	119.	Clackson, T. et al. (1991). "General Applications of PCR to Gene Cloning and Manipulation" Chapter 12 <i>In PCR: A Practical Approach</i> McPherson, M.J. et al. eds. IRL Press at Oxford University Press, pp. 187-214.	
	120.	Clackson, T. et al. (1991). "Making Antibody Fragments Using Phage Display Libraries," <i>Nature</i> 352:624-628.	
	121.	Corti, A. et al. (1992). "Oligomeric Tumour Necrosis Factor α Slowly Converts into Inactive Forms at Bioactive Levels," <i>Biochem. J.</i> 284(Pt3):905-910.	
	122.	Cramer, A. et al. (1996). "Construction and Evolution of Antibody-Phage Libraries by DNA Shuffling," <i>Nature Medicine</i> 2(1):100-102.	
	123.	Cross, A.S. et al. (1989). "Pretreatment with Recombinant Murine Tumor Necrosis Factor α /Cachectin and Murine Interleukin 1 α Protects Mice From Lethal Bacterial Infection," <i>The Journal of Experimental Medicine</i> 169:2021-2027.	
	124.	De Haard, H.J. et al. (1999). "A Large Non-Immunized Human Fab Fragment Phage Library That Permits Rapid Isolation and Kinetic Analysis of High Affinity Antibodies," <i>The Journal of Biological Chemistry</i> 274(26):18218-18230.	
	125.	Di Giovine, F. et al. (1988). "Tumour Necrosis Factor in Synovial Exudates," <i>Annals of the Rheumatic Diseases</i> 47:768-772.	
	126.	Dueñas, M. et al. (1996). "Selection of Phage Displayed Antibodies Based on Kinetic Constants," <i>Molecular Immunology</i> 33(7):279-285.	
	127.	Echtenacher, B. et al. (1990). "Requirement of Endogenous Tumor Necrosis Factor/Cachectin for Recovery from Experimental Peritonitis," <i>J. Immunol.</i> 145(11):3762-3766.	
	128.	Elliott, M.J. et al. (1994). "Randomised Double-Blind Comparison of Chimeric Monoclonal Antibody to Tumour Necrosis Factor α (cA2) versus Placebo In Rheumatoid Arthritis," <i>Lancet</i> 344:1105-1110.	
	129.	Elliott, M.J. et al. (1994). "Repeated Therapy with Monoclonal Antibody to Tumour Necrosis Factor α (cA2) in Patients with Rheumatoid Arthritis," <i>Lancet</i> 344:1125-1127.	
	130.	Engelmann, H. et al. (1989). "A Tumor Necrosis Factor-Binding Protein Purified to Homogeneity from Human Urine Protects Cells from Tumor Necrosis Factor Toxicity," <i>J. Biol. Chem.</i> 264(20):11974-11980.	
	131.	Engelmann, H. et al. (1990). "Two Tumor Necrosis Factor-Binding Proteins Purified from Human Urine," <i>J. Biol. Chem.</i> 265(3):1531-1536.	
	132.	English Abstract of Japanese Laid-Open publication 1-268645.	
EXAMINER:		DATE CONSIDERED:	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			

Form PTO-1449 SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Docket Number 273402602309	Application Number 10/702,681
		Applicant Deborah A. RATHJEN et al.	
		Filing Date November 5, 2003	Group Art Unit Not Yet Assigned
		Mailing Date February 18, 2004	

	133.	Espevik, T. and Nissen-Meyer, J. (1986). "A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes," <i>J. Immunol. Methods</i> 95:99-105.
	134.	Exley, A.R. et al. (1990). "Monoclonal Antibody to TNF in Severe Septic Shock," <i>The Lancet</i> 335:1275-1277.
	135.	Fendly et al. (1987). "Murine Monoclonal Antibodies Defining Neutralizing Epitopes on Tumor Necrosis Factor," <i>Hybridoma</i> 6(4):359-370.
	136.	Fiedler, V.B. et al. (1992). "Monoclonal Antibody to Tumor Necrosis Factor α Prevents Lethal Endotoxin Sepsis in Adult Rhesus Monkeys," <i>J. Lab. Clin. Med.</i> 120:574-588.
	137.	Fisher, C.J. Jr. et al. (1996). "Treatment of Septic Shock with the Tumor Necrosis Factor Receptor:Fc Fusion Protein," <i>N. Engl. J. Med.</i> 334(26):1697-1702.
	138.	Fomsgaard, A. et al. (1989). "Auto-Antibodies to Tumour Necrosis Factor α in Healthy Humans and Patients with Inflammatory Diseases and Gram-Negative Bacterial Infections," <i>Scand. J. Immunol.</i> 30:219-223.
	139.	Fong, Y. et al. (1989). "Antibodies to Cachectin/Tumor Necrosis Factor Reduce Interleukin 1 β and Interleukin 6 Appearance During Lethal Bacteremia," <i>J. Exp. Med.</i> 170:1627-1633.
	140.	Fournier, A. et al. (1989). "Applications of BOP Reagent in Solid Phase Peptide Synthesis," <i>Int. J. Peptide Protein Res.</i> 33:133-139.
	141.	Galloway, C. et al. (1991). "Monoclonal Anti-Tumor Necrosis Factor (TNF) Antibodies Protect Mouse and Human Cells from TNF Cytotoxicity," <i>J. Immunol. Methods</i> 140:37-43.
	142.	Gatanaga, T. et al. (1990). "Identification of TNF-LT Blocking Factor(s) in the Serum and Ultrafiltrates of Human Cancer Patients," <i>Lymphokine Research</i> 9(2):225-229.
	143.	Geysen, H.M. et al. (July 1984). "Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid" <i>Proc. Natl. Acad. Sci.</i> 81:3998-4002.
	144.	Gherardi, E. and Milstein, C. (1992). "Original and Artificial Antibodies," <i>Nature</i> 357(6375):201-202.
	145.	Grau, G.E. et al. (1987). "Tumor Necrosis Factor (Cachectin) As An Essential Mediator in Murine Cerebral Malaria," <i>Science</i> 237:1210-1212.
	146.	Griffiths, A.D. et al. (1993). "Human Anti-Self Antibodies With High Specificity From Phage Display Libraries," <i>The EMBO Journal</i> 12(2):725-734.
	147.	Gruss, H.J. and Dower, S.K. (1995). "The TNF Ligand Superfamily and Its Relevance for Human Diseases," <i>Cytokines and Mol. Ther.</i> 1:75-105.
	148.	Güssow, D. and Seemann, G. (1991). "Humanization of Monoclonal Antibodies" Chapter 5 <i>In Methods in Enzymology</i> Academic Press, Inc.: New York, NY. Vol. 203, pp. 99-121.
	149.	Haber, E. (1992). "Engineered Antibodies as Pharmacological Tools," <i>Immunol Rev.</i> 130:189-212.
	150.	Hasegawa, A. et al. (2003). "Modifying TNF α for Therapeutic Use: A Perspective on the TNF Receptor System," located at < http://bentham.org/mrmc1-1/murali/murali.html > last visited on January 9, 2004, eleven pages.

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

Form PTO-1449

**SUPPLEMENTAL INFORMATION
DISCLOSURE CITATION
IN AN APPLICATION**

(Use several sheets if necessary)

Docket Number 273402602309

Application Number 10/702,681

Applicant

Deborah A. RATHJEN et al.

Filing Date November 5, 2003

Group Art Unit Not Yet Assigned

Mailing Date February 18, 2004

151.	Hawkins, R.E. et al. (1992). "Selection of Phage Antibodies by Binding Affinity: Mimicking Affinity Maturation," <i>J. Mol. Biol.</i> 226:889-896.
152.	Hinshaw, L.B. et al. (1990). "Survival of Primates in LD ₁₀₀ Septic Shock Following Therapy with Antibody to Tumor Necrosis Factor (TNF α)," <i>Circ. Shock</i> 30:279-292.
153.	Hirai et al. (1987). "Production and Characterization of Monoclonal Antibodies to Human Tumor Necrosis Factor," <i>J. Immunol. Meth.</i> 96:57-62.
154.	Hodits, R.A. et al. (1995). "An Antibody Fragment from a Phage Display Library Competes for Ligand Binding to the Low Density Lipoprotein Receptor Family and Inhibits Rhinovirus Infection," <i>The Journal of Biological Chemistry</i> 270(41):24078-24085.
155.	Hohmann, H-P. et al. (1989). "Two Different Cell Types Have Different Major Receptors for Human Tumor Necrosis Factor (TNF α)," <i>The Journal of Biological Chemistry</i> 264(25):14927-14934.
156.	Holler, E. et al. (1995). "Modulation of Acute Graft-Versus-Host Disease After Allogeneic Bone Marrow Transplantation by Tumor Necrosis Factor α (TNF α) Release in the Course of Pretransplant Conditioning: Role of Conditioning Regimens and Prophylactic Application of a Monoclonal Antibody Neutralizing Human TNF α (MAK 195F)," <i>Blood</i> 86:890-899.
157.	Holliger, P. and Hoogenboom, H.R. (1995). "Artificial Antibodies and Enzymes: Mimicking Nature and Beyond," <i>TIBTECH</i> 13:7-9.
158.	Hoogenboom, H.R. (1992). "By-Passing Immunisation: Human Antibodies from Synthetic Repertoires of Germline V _H Gene Segments Rearranged <i>in Vitro</i> ," <i>J. Mol. Biol.</i> 227:381-388.
159.	Hoogenboom, H.R. (1997). "Designing and Optimizing Library Selection Strategies for Generating High-Affinity Antibodies," <i>TIBTECH</i> 15:62-70.
160.	Hoogenboom, H.R. et al. (1991). "Construction and Expression of Antibody-Tumor Necrosis Factor Fusion Proteins," <i>Molecular Immunology</i> 28(9):1027-1037.
161.	Hoogenboom, H.R. et al. (1991). "Multi-Subunit Proteins on the Surface of Filamentous Phage: Methodologies for Displaying Antibody (Fab) Heavy and Light Chains," <i>Nucleic Acids Research</i> 19(15):4133-4137.
162.	Hoogenboom, H.R. et al. (1992). "Building Antibodies from their Genes," <i>Immunological Reviews</i> 130:41-68.
163.	Idriss, H.T. and Naismith, J.H. (2000). "TNF α and the TNF Receptor Superfamily: Structure-Function Relationship(s)," <i>Microscopy Research and Technique</i> 50:184-195.
164.	Jespers, L.S. et al. (1994). "Guiding the Selection of Human Antibodies from Phage Display Repertoires to a Single Epitope of an Antigen," <i>BIO/TECHNOLOGY</i> 12:899-903.
165.	Kabat, E.A. (1991) <u>Sequences of Proteins of Immunological Interest</u> , 5th Edition, from <i>US Public Health Services</i> , NIH publication no. 91-3242, Table of Contents, pp. iii-xi.
166.	Kang, A.S. et al. (1991). "Antibody Redesign by Chain Shuffling From Random Combinatorial Immunoglobulin Libraries," <i>Proc. Natl. Acad. Sci. USA</i> 88:11120-11123.
167.	Kawasaki, H. et al. (1989). "Analysis of Endotoxin Fever in Rabbits by Using a Monoclonal Antibody to Tumor Necrosis Factor (Cachectin)," <i>Infection and Immunity</i> 57(10):3131-3135.
168.	Kohase, M. et al. (1986). "Induction of β_2 -Interferon by Tumor Necrosis Factor: A Homeostatic Mechanism in the Control of Cell Proliferation," <i>Cell</i> 45:659-666.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Docket Number 273402602309	Application Number 10/702,681
		Applicant Deborah A. RATHJEN et al.	
		Filing Date November 5, 2003	Group Art Unit Not Yet Assigned
		Mailing Date February 18, 2004	
	169.	Kunkel, S.L. et al. (1989). "Mechanisms That Regulate the Production and Effects of Tumor Necrosis Factor- α ," <i>Critical Rev. Immunol.</i> 9(2):93-117.	
	170.	Laune D. et al. (1998). "Peptide Models of Immunological Recognition: Paratope Dissection by Multiple Peptide Synthesis," <i>Clin. Chem. Lab. Med.</i> 36(6):367-71.	
	171.	Laune, D. et al. (2000). "Dissection of an Antibody Paratope into Peptides Discloses the Idiotope Recognized by the Cognate Anti-Idiotypic Antibody," <i>J. Immunol. Methods</i> 239(1-2):63-73.	
	172.	Liang et al. (1986). "Production and Characterization of Monoclonal Antibodies Against Recombinant Human Tumor Necrosis Factor/Cachectin," <i>Biochem. Biophys. Res. Comm.</i> 137(2):847-854.	
	173.	Loetscher, H. et al. (1990). "Molecular Cloning and Expression of the Human 55 kd Tumor Necrosis Factor Receptor," <i>Cell</i> 61:351-359.	
	174.	Love, T.W. et al. (1989). "Recombinant Antibodies Possessing Novel Effector Functions" Chapter 35 <i>In Methods in Enzymology</i> Academic Press, Inc.: New York, NY. Vol. 178, pp. 515-527.	
	175.	Lucas, R. et al. (1990). "Generation and Characterization of a Neutralizing Rat Anti-rmTNF- α Monoclonal Antibody," <i>Immunology</i> 71:218-223.	
	176.	MacDonald, T.T. et al. (1990). "Tumour Necrosis Factor-Alpha and Interferon-Gamma Production Measured at the Single Cell Level in Normal and Inflamed Human Intestine," <i>Clin. Exp. Immunol.</i> 81:301-305.	
	177.	Mahler, S.M. et al. (1997). "Cloning and Expression of Human V-Genes Derived From Phage Display Libraries as Fully Assembled Human Anti-TNF α Monoclonal Antibodies," <i>Immunotechnology</i> 3:31-43.	
	178.	Marks, J.D. (1992). "Molecular Evolution of Proteins on Filamentous Phage," <i>The Journal of Biological Chemistry</i> 267(23):16007-16010.	
	179.	Marks, J.D. et al. (1991). "Oligonucleotide primers for polymerase chain reaction amplification of human immunoglobulin variable genes and design of family-specific oligonucleotide probes" <i>Eur. J. Immunol.</i> 21(4):985-991.	
	180.	Marks, J.D. et al. (1991). "By-Passing Immunization: Human Antibodies from V-Gene Libraries Displayed on Phage," <i>J. Mol. Biol.</i> 222:581-597.	
	181.	Mathison, J.C. et al. (1988). "Participation of Tumor Necrosis Factor in the Mediation of Gram Negative Bacterial Lipopolysaccharide-Induced Injury in Rabbits," <i>J. Clin. Invest.</i> 81:1925-1937.	
	182.	McCafferty, J. et al. (1990). "Phage Antibodies: Filamentous Phage Displaying Antibody Variable Domains," <i>Nature</i> 348:552-554.	
	183.	Meager et al. (1987). "Preparation and Characterization of Monoclonal Antibodies Directed Against Antigenic Determinants of Recombinant Human Tumour Necrosis Factor (rTNF)," <i>Hybridoma</i> 6(3):305-311.	
	184.	Möller, A. et al. (1990). "Monoclonal Antibodies to Human Tumor Necrosis Facctor α : In Vitro and In vivo Application," <i>Cytokine</i> 2(3):162-169.	
EXAMINER:		DATE CONSIDERED:	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			

Form PTO-1449

**SUPPLEMENTAL INFORMATION
DISCLOSURE CITATION
IN AN APPLICATION**

(Use several sheets if necessary)

Docket Number 273402602309

Application Number 10/702,681

Applicant

Deborah A. RATHJEN et al.

Filing Date November 5, 2003

Group Art Unit Not Yet Assigned

Mailing Date February 18, 2004

185.	Moreland, L.W. et al. (1997). "Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)-Fc Fusion Protein," <i>N. Engl. J. Med.</i> 337(3):141-147.
186.	Morrison, S.L. (1985). "Transfectomas Provide Novel Chimeric Antibodies," <i>Science</i> 229:1202-1207.
187.	Morrison, S.L. (1989). "Genetically Engineered (Chimeric) Antibodies," <i>Hospital Practice</i> pp. 65-80.
188.	Mountain, A. and Adair, J.R. (1992). "Engineering Antibodies For Therapy" Chapter 1 <i>In Biotechnology and Genetic Engineering Reviews</i> Vol. 10, pp. 1-142.
189.	Murch, S.H. et al. (1991). "Serum Concentrations of Tumour Necrosis Factor α in Childhood Chronic Inflammatory Bowel Disease," <i>Gut</i> 32:913-917.
190.	Nagai, M. et al. (1988). "Antibody to Tumor Necrosis Factor (TNF) Reduces Endotoxin Fever," <i>Experientia</i> 44:606-607.
191.	Natanson, C. et al., (1994) "Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis" <i>Ann. Int. Med.</i> , 120(9):771-783.
192.	Nawroth, P.P. and Stern, D.M. (1986). "Modulation of Endothelial Cell Hemostatic Properties by Tumor Necrosis Factor," <i>J. Exp. Med.</i> 163:740-745.
193.	Neda, H. (1987) "Analysis of the tumor necrosis factor (TNF) receptor of various tumor cells" <i>Sapporo Med J.</i> 56(2):305-317.
194.	Nissim, A. et al. (1994). "Antibody Fragments From a 'Single Pot' Phage Display Library as Immunochemical Reagents," <i>The EMBO Journal</i> 13(3):692-698.
195.	Nophar, Y. et al. (1990). "Soluble Forms of Tumor Necrosis Factor Receptors (TNF-Rs). The cDNA for the Type I TNF-R, Cloned Using Amino Acid Sequence Data of its Soluble Form, Encodes both the Cell Surface and a Soluble Form of the Receptor," <i>EMBO J.</i> 9(10):3269-3278.
196.	Olsson, P.G. et al. (1991). "Antigenicity of Mouse Monoclonal Antibodies: A Study on the Variable Region of the Heavy Chain," <i>J. Theor. Biol.</i> 151:111-122.
197.	Opal, S.M. et al. (1990). "Efficacy of a Monoclonal Antibody Directed Against Tumor Necrosis Factor in Protecting Neutropenic Rats from Lethal Infection with <i>Pseudomonas aeruginosa</i> ," <i>The Journal of Infectious Diseases</i> 161:1148-1152.
198.	Opposition documents: English Translation of BASF's Opposition dated 02/24/1997.
199.	Opposition documents: English Translation of BASF's Request for Restitutio in Integrum dated 06/05/2000.
200.	Opposition documents: English Translation of BASF's Statement of Grounds of Appeal dated 05/29/2000.
201.	Opposition documents: English Translation of BASF's Submission dated 05/29/1998.
202.	Opposition documents: English Translation of BASF's Submission dated 08/30/1999.
203.	Opposition file history of European Patent Application No. 90911467.0, Opposition No. 2116, Publication No. 0 486 526, (02/24/1997-01/26/2001), pages 1-373.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Docket Number 273402602309	Application Number 10/702,681
		Applicant Deborah A. RATHJEN et al.	
		Filing Date November 5, 2003	Group Art Unit Not Yet Assigned
		Mailing Date February 18, 2004	
	204.	Pantophlet, R. et al. (2003). "Fine Mapping of the Interaction of Neutralizing and Nonneutralizing Monoclonal Antibodies with the CD4 Binding Site of Human Immunodeficiency Virus Type 1 gp120," <i>Journal of Virology</i> 77(1):642-658.	
	205.	Pantophlet, R. et al. (2003). "Hyperglycosylated Mutants of Human Immunodeficiency Virus (HIV) Type 1 Monomeric gp120 as Novel Antigens for HIV Vaccine Design," <i>Journal of Virology</i> 77(10):5889-5901.	
	206.	Pennica, D. et al., (1984) "Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin" <i>Nature</i> 312:724-729.	
	207.	Piguet, P.F. et al. (1987). "Tumor Necrosis Factor/Cachectin is an Effector of Skin and Gut Lesions of the Acute Phase of Graft-vs.-Host Disease," <i>J. Exp. Med.</i> 166:1280-1289.	
	208.	Pini, A. et al. (1998). "Design and Use of a Phage Display Library," <i>The Journal of Biological Chemistry</i> 273(34):21769-21776.	
	209.	Rademacher, T.W. et al. (1988). "The Role of IgG Glycoforms in the Pathogenesis of Rheumatoid Arthritis," <i>Springer Seminars in Immunopathology</i> 10:231-249.	
	210.	Rader, C. et al. (1998). "A Phage Display Approach for Rapid Antibody Humanization: Designed Combinatorial V Gene Libraries," <i>Proc. Natl. Acad. Sci. USA</i> 95:8910-8915.	
	211.	Rankin, E.C.C. et al. (1995). "The Therapeutic Effects of an Engineered Human Anti-Tumour Necrosis Factor Alpha Antibody (CDP571) in Rheumatoid Arthritis," <i>Br. J. Rheumatol.</i> 34(4):334-342.	
	212.	Rathjen, D.A. and Underwood, P.A. (1986) "Identification of antigenic determinants on insulin recognized by monoclonal antibodies" <i>Mol. Immunol.</i> 23(4):441-450.	
	213.	Rathjen, D.A. et al. (1993). "Differential Effects of Small Tumour Necrosis Factor- α Peptides on Tumour Cell Cytotoxicity, Neutrophil Activation and Endothelial Cell Procoagulant Activity," <i>Immunology</i> 80:293-299.	
	214.	Reinhart, K. et al. (1995). "Treatment of Severe Sepsis with Anti-TNF Monoclonal Antibody MAK 195F: Dose Dependent Reduction of Mortality in Patients with Elevated IL-6 Serum-Levels," <i>Supplement to Clin. Intens. Care</i> 6(2):82 (Abstract.)	
	215.	Remick, D.G. et al. (1987). "Acute <i>in Vivo</i> Effects of Human Recombinant Tumor Necrosis Factor," <i>Lab. Invest.</i> 56(6):583-590.	
	216.	Riechmann, L. et al. (1988). "Reshaping Human Antibodies for Therapy," <i>Nature</i> 332:323-327.	
	217.	Ruddle, N.H. et al. (1990). "An Antibody to Lymphotoxin and Tumor Necrosis Factor Prevents Transfer of Experimental Allergic Encephalomyelitis," <i>J. Exp. Med.</i> 172:1193-1200.	
	218.	Saiki, R.K. et al. (1985). "Enzymatic Amplification of B-Globin Genomic Sequences and Restriction Site Analysis for Diagnosis of Sickle Cell Anemia," <i>Science</i> 230:1350-1354.	
	219.	Salat, C. et al. (1996). "Hemostatic Parameters in Sepsis Patients Treated With Anti-TNF α -Monoclonal Antibodies," <i>Shock</i> 6(4):233-237.	
	220.	Sambrook, J. et al. (1989). "Screening Expression Libraries with Antibodies and Oligonucleotides" Chapter 12 <i>In Molecular Cloning: A Laboratory Manual</i> , Cold Spring Harbor Laboratory Press, Cold	
EXAMINER:		DATE CONSIDERED:	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			

Form PTO-1449 SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Docket Number 273402602309	Application Number 10/702,681
		Applicant Deborah A. RATHJEN et al.	
		Filing Date November 5, 2003	Group Art Unit Not Yet Assigned
		Mailing Date February 18, 2004	
		Spring Harbor, NY. pp. 12.1 - 12.44.	
	221.	Schall, T. et al. (1990). "Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor," <i>Cell</i> 61:361-370.	
	222.	Schier, R. et al. (1995). "In vitro and in vivo Characterization of a Human Anti-c-erbB-2 Single-Chain Fv Isolated From a Filamentous Phage Antibody Library," <i>Immunotechnology</i> 1:73-81.	
	223.	Selinsky, C.L. et al. (1998). "Multifaceted Inhibition of Anti-Tumour Immune Mechanisms By Soluble Tumour Necrosis Factor Receptor Type I," <i>Immunology</i> 94:88-93.	
	224.	Shalaby, M. R. et al. (1989). "Prevention of the Graft-Versus-Host Reaction in Newborn Mice by Antibodies to Tumor Necrosis Factor-Alpha," <i>Transplantation</i> 47(6):1057-1061.	
	225.	Shalaby, M. R. et al. (1992). "Development of Humanized Bispecific Antibodies Reactive with Cytotoxic Lymphocytes and Tumor Cells Overexpressing the <i>HER2</i> Protooncogene," <i>J. Exp. Med.</i> 175:217-225.	
	226.	Shalaby, M.R. et al. (1988). "The Involvement of Human Tumor Necrosis Factors α and β in the Mixed Lymphocyte Reaction," <i>J. Immunol.</i> 141(2):499-503.	
	227.	Shearman, C.W. et al. (1991). "Construction, Expression and Characterization of Humanized Antibodies Directed Against the Human α/β T Cell Receptor," <i>The Journal of Immunology</i> 147(12):4366-4373.	
	228.	Sheehan, K. et al. (1989). "Generation and Characterization of Hamster Monoclonal Antibodies that Neutralize Murine Tumor Necrosis Factors," <i>J. Immunol.</i> 142(11):3884-3893.	
	229.	Shimamoto, Y. et al. (1988). "Monoclonal Antibodies Against Human Recombinant Tumor Necrosis Factor: Prevention of Endotoxic Shock," <i>Immunology Letters</i> 17:311-318.	
	230.	Silva, A.T. (1990). "Prophylactic and Therapeutic Effects of a Monoclonal Antibody to Tumor Necrosis Factor α in Experimental Gram-Negative Shock," <i>J. Infect. Dis.</i> 162:421-427.	
	231.	Smith, C.A. et al. (1990). "A Receptor for Tumor Necrosis Factor Defines an Unusual Family of Cellular and Viral Proteins," <i>Science</i> 248:1019-1023.	
	232.	Socher, S.H. et al. (December 1987) "Antibodies against amino acids 1-15 tumor necrosis factor block its binding to cell-surface receptor" <i>Proc. Natl. Acad. Sci. USA Biochemistry</i> 84:8829-8833.	
	233.	Stack, W.A. et al. (1997). "Randomised Controlled Trial of CDP571 Antibody to Tumour Necrosis Factor- α in Crohn's Disease," <i>The Lancet</i> 349:521-524.	
	234.	Sun, X-M. and Hsueh, W. (1988). "Bowel Necrosis Induced by Tumor Necrosis Factor in Rats is Mediated by Platelet-Activating Factor," <i>J. Clin. Invest.</i> 81:1328-1331.	
	235.	Tavernier, J. et al. 1990). "Analysis of the Structure-Function Relationship of Tumour Necrosis Factor. Human/Mouse Chimeric TNF Proteins: General Properties and Epitope Analysis," <i>J. Mol. Biol.</i> 211:493-501.	
	236.	Tomlinson, I.M. et al. (1992) "The repertoire of human germline V_H sequences reveals about fifty groups of V_H segments with different hypervariable loops" <i>J. Mol. Biol.</i> 227:776-798.	
	237.	Tracey, K.J. et al. (1986). "Shock and Tissue Injury Induced by Recombinant Human Cachectin," <i>Science</i> 234:470-474.	
EXAMINER:		DATE CONSIDERED:	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			

Form PTO-1449 SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Docket Number 273402602309	Application Number 10/702,681
		Applicant Deborah A. RATHJEN et al.	
		Filing Date November 5, 2003	Group Art Unit Not Yet Assigned
		Mailing Date February 18, 2004	
	238.	Tracey, K.J. et al., (1987) "Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia" <i>Nature</i> 330:662-664.	
	239.	Tyutyulkova, S. and Paul S. (1994). "Selection of Functional Human Immunoglobulin Light Chains from a Phage-Display Library," <i>Appl. Biochem. Biotechnol.</i> May-June 47(2-3):191-197.	
	240.	Van der Poll, T. et al. (1991). "Tumor Necrosis Factor and the Disbalance Between Coagulant and Anticoagulant Mechanisms in Septicemia" <i>In Update In Intensive Care and Emergency Medicine</i> 14 Vincent, J.L. ed. Springer-Verlar: Berlin pp.269-273.	
	241.	Van der Poll, T. et al. (1994). "Differential Effects of Anti-Tumor Necrosis Factor Monoclonal Antibodies on Systemic Inflammatory Responses in Experimental Endotoxemia in Chimpanzees," <i>Blood</i> 83:446-451.	
	242.	Van Deventer, S.J.H. et al. (1990). "Experimental Endotoxemia in Humans: Analysis of Cytokine Release and Coagulation, Fibrinolytic, and Complement Pathway," <i>Blood</i> 76:2520-2526.	
	243.	Van Dullemen, H.M. et al. (1995). "Treatment of Crohn's Disease with Anti-Tumour Necrosis Factor Chimeric Monoclonal Antibody (cA2)," <i>Gastroenterology</i> 109(1):129-135.	
	244.	van Ostade, X. et al. (1994). "Human Tumor Necrosis Factor Mutants with Preferential Binding to and Activity on Either the R55 or R75 Receptor," <i>Eur. J. Biochem.</i> 220:771-779.	
	245.	van Ostade, X. et al. (1994). "Structure-activity Studies of Human Tumour Necrosis Factors," <i>Protein Eng.</i> 7(1):5-22.	
	246.	Vandenbeelee, P. et al. (1995). "Two Tumour Necrosis Factor Receptors: Structure and Function," <i>Trends in Cell Biology</i> 5:392-399.	
	247.	Vaughan, T.J. et al. (1996). "Human Antibodies With Sub-Nanomolar Affinities Isolated From a Large Non-Immunized Phage Display Library," <i>Nature Biotechnology</i> 14:309-314.	
	248.	Vilcek, J. et al. (1986). "Fibroblast Growth Enhancing Activity of Tumor Necrosis Factor and its Relationship to Other Polypeptide Growth Factors," <i>J. Exp. Med.</i> 163:632-643.	
	249.	Von Asmuth, E.J.U. et al. (1990). "Tumour Necrosis Factor Alpha (TNF- α) and Interleukin 6 in a Zymosan-Induced Shock Model," <i>Scand. J. Immunol.</i> 32:313-319.	
	250.	Waldmann, T.A. (1991). "Monoclonal Antibodies in Diagnosis and Therapy," <i>Science</i> 252:1657-1662.	
	251.	Wallach, D. et al. (1999). "Tumor Necrosis Factor Receptor and Fas Signaling Mechanisms," <i>Annu. Rev. Immunol.</i> 17:331-367.	
	252.	Ward, E.S. et al. (1989). "Binding Activities of a Repertoire of Single Immunoglobulin Variable Domains Secreted From <i>Escherichia coli</i> ," <i>Nature</i> 341:544-546.	
	253.	Watanabe, N. et al. (1988) "Synergistic cytotoxicity of recombinant human TNF and various anti-cancer drugs" <i>Immunopharmacol. Immunotoxicol.</i> 10(1):117-127.	
	254.	Watanabe, N. et al., (1986) "Analysis of the TNF receptors of kym cells by affinity cross-linking" Japanese article from Gan To Kagaku Ryoho (<i>Jpn. J. Cancer Chemotherapy</i>) 13(8):2625-2629, and English translation, 5 pages.	
	255.	Winter, G. and Milstein, C. (1991). "Man-made Antibodies," <i>Nature</i> 349:293-299.	
EXAMINER:		DATE CONSIDERED:	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			

Form PTO-1449

**SUPPLEMENTAL INFORMATION
DISCLOSURE CITATION
IN AN APPLICATION**

(Use several sheets if necessary)

Docket Number 273402602309

Application Number 10/702,681

Applicant

Deborah A. RATHJEN et al.

Filing Date November 5, 2003

Group Art Unit Not Yet Assigned

Mailing Date February 18, 2004

- | | |
|------|--|
| 256. | Winter, G. et al. (1993). "Humanized Antibodies," <i>Immunology Today</i> 14(6):243-245. |
| 257. | Winter, G. et al. (1994). "Making Antibodies by Phage Display Technology," <i>Annu. Rev. Immunol.</i> 12:433-455. |
| 258. | Yamauchi et al. (1989). "Intracellular Hydroxyl Radical Production Induced by Recombinant Human Tumor Necrosis Factor and Its Implication in the Killing of Tumor Cell <i>In Vitro</i> ," <i>Cancer Res.</i> 49:1671-1675. |
| 259. | Yang, W.P. et al. (1995). "CDR Walking Mutagenesis for the Affinity Maturation of a Potent Human Anti-HIV-1 Antibody into the Picomolar Range," <i>J. Mol. Biol.</i> 254(3):392-403. |
| 260. | Zebedee, S.L. et al. (1992). "Human Combinatorial Antibody Libraries to Hepatitis B Surface Antigen," <i>Proc. Natl. Acad. Sci. USA</i> 89:3175-3179. |
| 261. | Zwierzina, H. (1993) "Practical aspects of cytokine therapy" <i>Stem Cells</i> 11:144-153. |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.